{ "@context": "https://clearank.com/llms.txt", "@type": "clearank:AssetAnalysis", "url": "https://clearank.com/stock/capr-stock-analysis/", "dataUrl": "https://clearank.com/stock/capr-stock-analysis/data.json", "title": "Capricor Therapeutics, Inc (CAPR) Stock Forecast (2026)", "description": "Capricor Therapeutics, Inc. (CAPR) stock: Healthcare, Biotechnology. $483M market cap. AI rating, technicals, 2030 forecast and trade plans.", "headline": "Capricor Therapeutics, Inc. (CAPR)", "published": "2026-09-03T06:30:28+00:00", "modified": "2026-09-11T13:17:25.23+00:00", "generated": "2026-09-11T21:01:07.448Z", "language": "en-US", "publisher": { "name": "CleaRank", "url": "https://clearank.com/" }, "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.", "asset": { "ticker": "CAPR", "name": "Capricor Therapeutics, Inc.", "type": "Common Stock", "exchange": "NASDAQ", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "country": "United States", "website": "https://www.capricor.com" }, "quote": { "price": 8.3, "previousClose": 8.64, "change": -0.34, "changePercent": -3.94, "open": 8.58, "high": 8.7, "low": 8.18, "volume": 2912200, "averageVolume": 4825770, "marketCap": 482553608, "fiftyTwoWeekHigh": 40.37, "fiftyTwoWeekLow": 2.96, "marketOpen": false, "asOf": "2026-09-11T13:17:24.000Z" }, "statistics": { "pe": -3.6747788960954786, "eps": -2.45, "dividendYield": 0, "beta": 0.722, "priceToSales": null, "priceToBook": 2.0391788, "revenueTtm": 0, "grossMargin": null, "returnOnEquity": -0.737 }, "technicals": { "rsi": 60.2, "macd": -0.37, "sma50": 11.62, "sma200": 23.42, "rsiSignal": "Bullish", "trend": "Bearish", "pricePosition": "Bearish", "macdSignal": "Bearish", "rating": "Bearish" }, "analysis": { "rating": "Hold", "score": 59, "consensus": "Hold", "fairValue": 8.3, "analystTarget": 26.5, "analystCount": 9, "wallStreetConsensus": "Hold", "generatedAt": "2026-09-11T13:17:24.000Z", "priceAtAnalysis": 8.3, "volatility": { "daily": 12.98, "risk": "volatile" } }, "tradePlan": { "bias": "Neutral", "conservativeEntry": 8.22, "aggressiveEntry": 8.3, "stopLoss": 6.62, "stopLossPercent": 19.47, "targets": [ 8.46, 8.63, 8.87 ] }, "projections": { "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets", "years": [ { "year": 2027, "downside10th": 4.14, "base": 7.86, "upside90th": 14.91 }, { "year": 2028, "downside10th": 3.01, "base": 7.44, "upside90th": 18.41 }, { "year": 2029, "downside10th": 2.32, "base": 7.04, "upside90th": 21.37 }, { "year": 2030, "downside10th": 1.85, "base": 6.67, "upside90th": 24.02 }, { "year": 2031, "downside10th": 1.51, "base": 6.31, "upside90th": 26.45 }, { "year": 2032, "downside10th": 1.24, "base": 5.97, "upside90th": 28.71 }, { "year": 2033, "downside10th": 1.04, "base": 5.66, "upside90th": 30.82 }, { "year": 2034, "downside10th": 0.87, "base": 5.35, "upside90th": 32.8 }, { "year": 2035, "downside10th": 0.74, "base": 5.07, "upside90th": 34.66 }, { "year": 2036, "downside10th": 0.63, "base": 4.8, "upside90th": 36.41 } ] }, "faqCount": 8, "sources": [ "TwelveData", "Wall Street consensus" ], "sections": [ { "id": "price", "title": "CAPR Price Analysis" }, { "id": "market-metrics", "title": "Market Metrics", "facts": { "Open": "$8.58", "Day Range": "$8.18 to $8.70", "Prev Close": "$8.64", "Volume": "2.91M", "52-Week Range": "$2.96 to $40.37", "Market Cap": "$482.55M" } }, { "id": "peer-benchmarking", "title": "Peer Benchmarking", "text": [ "Sector Position Analysis" ] }, { "id": "analysis", "title": "CAPR Analysis", "text": [ "Capricor Therapeutics (CAPR) is trading below its 50-day and 200-day moving averages ($11.62 and $23.42), indicating a bearish trend. The 50-day moving average is acting as resistance at $11.62, while the 200-day moving average is at $23.42. The Relative Strength Index (RSI) is at 60.2, which is in the bullish momentum territory, but the MACD at -0.37 suggests weakening momentum. Key support levels are not clearly defined given the limited trading history, but the current price of $8.30 is below recent moving averages. Volume on the latest trading day was 2,912,200, which is below the average volume of 4,825,770, suggesting subdued investor interest.", "Insiders have sold a total of $8.4 million worth of Capricor Therapeutics (CAPR) stock across 24 transactions, with no reported purchases, indicating a lack of confidence from management.", "Capricor Therapeutics (CAPR) reported an EPS of -0.70 against an estimate of -0.58 for the quarter ending August 13, 2026, a miss of 20.69%.", "The median Wall Street price target for CAPR is $26.50, representing a potential upside of 219.3% from the current trading price of $8.30.", "While the price target suggests upside, the Wall Street consensus is 'Hold', with 6 out of 9 analysts rating the stock as such, reflecting a cautious stance.", "The 6-12 month outlook for Capricor Therapeutics (CAPR) is cautiously mixed. While the median Wall Street price target of $26.50 suggests significant upside potential, the current trading price below key moving averages and substantial insider selling paint a bearish near-term picture. The company's recent earnings miss further adds to the uncertainty. Key catalysts could include positive clinical trial results or regulatory approvals, which could drive the stock towards the higher end of analyst targets. Conversely, continued operational challenges, further earnings disappointments, or a lack of progress in its pipeline could lead to a retest of lower price levels, potentially towards the downside projection of $1.85 in the long range." ], "lists": { "ProTips": [ "Given the significant insider selling and recent earnings miss, consider a risk-defined approach to any potential long positions in CAPR, potentially utilizing stop-losses below key technical support levels.", "The RSI is in bullish territory (60.2), but the MACD suggests weakening momentum. Monitor for a potential divergence or confirmation signal before establishing a position.", "With a median Wall Street price target of $26.50, investors may want to monitor analyst commentary and clinical trial updates closely for potential catalysts that could drive the stock towards this target." ] }, "catalysts": [ { "type": "Bearish", "title": "Significant Insider Selling", "text": "Insiders have sold a total of $8.4 million worth of Capricor Therapeutics (CAPR) stock across 24 transactions, with no reported purchases, indicating a lack of confidence from management.", "source": "Insider Transactions" }, { "type": "Bearish", "title": "Recent Earnings Miss", "text": "Capricor Therapeutics (CAPR) reported an EPS of -0.70 against an estimate of -0.58 for the quarter ending August 13, 2026, a miss of 20.69%.", "source": "Earnings Report" }, { "type": "Bullish", "title": "High Median Analyst Price Target", "text": "The median Wall Street price target for CAPR is $26.50, representing a potential upside of 219.3% from the current trading price of $8.30.", "source": "Wall Street Analysts" }, { "type": "Neutral", "title": "Mixed Analyst Ratings", "text": "While the price target suggests upside, the Wall Street consensus is 'Hold', with 6 out of 9 analysts rating the stock as such, reflecting a cautious stance.", "source": "Wall Street Analysts" } ] }, { "id": "key-statistics", "title": "Key Statistics", "text": [ "Capricor Therapeutics (CAPR) exhibits a negative EPS of -2.45, making its P/E ratio mathematically negative and rendering traditional valuation metrics like P/E and PEG unreliable. The company's revenue growth is not provided, and its current market capitalization is approximately $482.6 million. The sector median P/E is 31.9 and the median ROE is 6.9%, against which CAPR's profitability metrics are not comparable due to its loss-making status. Given the lack of positive earnings and revenue growth data, the fundamental picture is challenging. The significant insider selling further raises concerns about the company's near-term financial health and prospects.", "Capricor Therapeutics (CAPR) reported a significant earnings miss in its most recent quarter ending August 13, 2026, with an actual EPS of -0.70 against an estimate of -0.58, a surprise of -20.69%. This miss was accompanied by a substantial 57.96% price increase, suggesting market reaction was driven by factors other than the earnings report itself. Prior to this, the company beat estimates in Q2 2026 but missed in Q1 2026, indicating an inconsistent earnings performance.", "Capricor Therapeutics (CAPR) faces significant risks including substantial insider selling totaling $8.4 million, indicating a lack of confidence from management. The company is currently loss-making with a negative EPS of -2.45 and is trading below key moving averages, signaling bearish technical momentum. Also, the most recent earnings report showed a significant miss, raising concerns about operational execution and future profitability." ], "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "Market Cap", "cells": [ "482.55M" ] }, { "label": "P/E Ratio", "cells": [ "N/A (Negative EPS)" ] }, { "label": "EPS (TTM)", "cells": [ "-2.45" ] }, { "label": "Dividend Yield", "cells": [ "0.00%" ] }, { "label": "52 Week High", "cells": [ "40.37" ] }, { "label": "52 Week Low", "cells": [ "2.96" ] } ] } ] }, { "id": "technical-indicators", "title": "Technical Indicators", "text": [ "Technical Rating Bearish RSI Bullish SMA Cross Bearish Price vs SMA Bearish MACD Bearish Moving averages show a lagging Death Cross (50-day: $11.62, 200-day: $23.42), price is trading below the 50-day SMA." ], "facts": { "RSI": "Bullish", "SMA Cross": "Bearish", "Price vs SMA": "Bearish", "MACD": "Bearish" }, "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "RSI (14)", "cells": [ "60.20" ] }, { "label": "MACD", "cells": [ "-0.37" ] }, { "label": "SMA 50", "cells": [ "11.62" ] }, { "label": "SMA 200", "cells": [ "23.42" ] } ] } ] }, { "id": "correlations", "title": "Market Correlations", "text": [ "How this stock moves relative to other assets", "Based on 1 year of daily price data. Correlations may vary over different time periods." ], "facts": { "Correlation with S&P 500 (SPY)": "+0.10", "Correlation with Nasdaq 100 (QQQ)": "+0.10", "Correlation with Bitcoin (BTC)": "+0.15", "Correlation with Gold (XAU)": "-0.04" } }, { "id": "trade-plans", "title": "CAPR Trade Plans", "text": [ "Specific entry, exit, and risk management levels", "Enter now if confident", "Volatility-Adjusted Stop Loss Calculated based on RSI (60.2) and current market volatility", "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3" ], "facts": { "TARGET 1": "$8.464", "TARGET 2": "$8.628", "TARGET 3": "$8.874", "STOP LOSS": "$6.617" } }, { "id": "risk", "title": "Risk & Volatility", "facts": { "Daily Volatility": "12.98%" }, "lists": { "Risk considerations": [ "Monitor position sizing based on current volatility levels", "Consider stop-loss placement beyond recent price range", "Diversification helps mitigate single-stock risk exposure" ] } }, { "id": "growth", "title": "Growth of $10,000", "text": [ "A $10,000 investment in CAPR in September 2016 would be worth about $2,112 today, compared with about $35,030 for the same investment in the S&P 500 benchmark." ] }, { "id": "monte-carlo", "title": "Monte Carlo Projection (10yr)", "text": [ "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CAPR today could grow to about $5,782 by 2036 in the base case, with a bull case near $43,866 and a bear case around $762. Projections are statistical simulations, not guarantees." ] }, { "id": "price-prediction", "title": "CAPR Stock Price Prediction: 2030", "text": [ "CleaRank's simulation projects a price near $6.67 for CAPR by 2030 in the base case, from $8.30 today (0.8x over 4 years). The downside path ends near $1.85. These are outcomes of a Monte Carlo simulation run on CAPR's historical return distribution, not price targets, and they assume no dividends are reinvested.", "Method: 10,000 simulated price paths using CAPR's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice." ], "tables": [ { "caption": "CAPR simulated price paths by year", "columns": [ "Year", "Downside (10th pct)", "Base case", "Upside (90th pct)" ], "rows": [ { "label": "2027", "cells": [ "$4.14", "$7.86", "$14.91" ] }, { "label": "2028", "cells": [ "$3.01", "$7.44", "$18.41" ] }, { "label": "2029", "cells": [ "$2.32", "$7.04", "$21.37" ] }, { "label": "2030", "cells": [ "$1.85", "$6.67", "$24.02" ] }, { "label": "2031", "cells": [ "$1.51", "$6.31", "$26.45" ] }, { "label": "2032", "cells": [ "$1.24", "$5.97", "$28.71" ] }, { "label": "2033", "cells": [ "$1.04", "$5.66", "$30.82" ] }, { "label": "2034", "cells": [ "$0.8742", "$5.35", "$32.80" ] }, { "label": "2035", "cells": [ "$0.7414", "$5.07", "$34.66" ] }, { "label": "2036", "cells": [ "$0.6326", "$4.80", "$36.41" ] } ] } ] }, { "id": "people-also-watch", "title": "People Also Watch", "links": [ { "text": "ISRG Intuitive Surgical Inc. NASDAQ $358.08 +1.37%", "url": "https://clearank.com/stock/intuitive-surgical-isrg/" }, { "text": "LEGN Legend Biotech Corporation NASDAQ $19.91 -2.83%", "url": "https://clearank.com/stock/legend-biotech-legn/" }, { "text": "MRNA Moderna Inc. NASDAQ $148.15 +8.44%", "url": "https://clearank.com/stock/moderna-mrna/" }, { "text": "PFE Pfizer Inc. NYSE $27.78 -0.0360%", "url": "https://clearank.com/stock/pfizer-pfe/" }, { "text": "HCA HCA Healthcare, Inc. NYSE $417.37 -1.06%", "url": "https://clearank.com/stock/hca-healthcare-hca/" }, { "text": "MOH Molina Healthcare Inc. NYSE $200.28 +3.17%", "url": "https://clearank.com/stock/moh-stock-analysis/" }, { "text": "ABT Abbott Laboratories NYSE $103.36 -1.78%", "url": "https://clearank.com/stock/abbott-laboratories-abt/" }, { "text": "FBRX Forte Biosciences, Inc. NASDAQ $76.99 +0.00%", "url": "https://clearank.com/stock/fbrx-stock-analysis/" } ] }, { "id": "related-comparisons", "title": "Popular Comparisons", "links": [ { "text": "COST vs WMT Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/cost-vs-wmt/" }, { "text": "Gold vs Bitcoin Analysis and Targets Head-to-head analysis →", "url": "https://clearank.com/compare/gold-vs-bitcoin/" }, { "text": "AMAT vs LRCX Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/amat-vs-lrcx/" } ] }, { "id": "insider-trading", "title": "CAPR Insider Trading Analysis", "facts": { "Bought": "None", "Sold": "$8.4M", "Insiders": "5", "Avg Transaction": "$836.6K" }, "tables": [ { "caption": "Recent insider transactions in CAPR", "columns": [ "Date", "Insider", "Type", "Shares", "Value" ], "rows": [ { "label": "Apr 1, 2026", "cells": [ "SABAR KARIMAH ES Director", "Sell", "115.0K", "$3.5M" ] }, { "label": "May 1, 2026", "cells": [ "KRASNEY KAREN General Counsel", "Sell", "25.0K", "$792.5K" ] }, { "label": "May 1, 2026", "cells": [ "BERGMANN ANTHONY Chief Financial Officer", "Sell", "25.0K", "$792.5K" ] }, { "label": "Mar 31, 2026", "cells": [ "BERGMANN ANTHONY Chief Financial Officer", "Sell", "25.0K", "$753.2K" ] }, { "label": "Mar 31, 2026", "cells": [ "KRASNEY KAREN General Counsel", "Sell", "25.0K", "$752.9K" ] }, { "label": "Jun 25, 2026", "cells": [ "BERGMANN ANTHONY Chief Financial Officer", "Sell", "24.1K", "$732.2K" ] }, { "label": "Jun 25, 2026", "cells": [ "KRASNEY KAREN General Counsel", "Sell", "24.1K", "$732.2K" ] }, { "label": "Apr 2, 2026", "cells": [ "SABAR KARIMAH ES Director", "Sell", "7.5K", "$240.9K" ] }, { "label": "Jun 24, 2026", "cells": [ "BERGMANN ANTHONY Chief Financial Officer", "Sell", "900", "$27.0K" ] }, { "label": "Jun 24, 2026", "cells": [ "KRASNEY KAREN General Counsel", "Sell", "900", "$27.0K" ] } ] } ], "links": [ { "text": "SEC Form 4", "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Capricor+Therapeutics%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany" } ] }, { "id": "faq", "title": "Frequently Asked Questions" } ], "faq": [ { "question": "Is Capricor Therapeutics (CAPR) stock a buy?", "answer": "Capricor Therapeutics (CAPR) is currently rated a 'Hold' by Wall Street analysts, with a consensus score of 61 out of 100. While the median price target of $26.50 suggests significant upside potential from the current $8.30, substantial insider selling and a recent earnings miss present considerable risks." }, { "question": "What is Capricor Therapeutics' (CAPR) price target?", "answer": "The median analyst price target for Capricor Therapeutics (CAPR) is $26.50, with a high of $54.00 and a low of $7.00. This median target represents a potential upside of 219.3% from the current stock price of $8.30." }, { "question": "What are the biggest risks for Capricor Therapeutics (CAPR)?", "answer": "The primary risks for Capricor Therapeutics (CAPR) include significant insider selling totaling $8.4 million, a negative EPS of -2.45, and trading below key moving averages. The company also recently reported a substantial earnings miss, raising concerns about its operational performance." }, { "question": "How is Capricor Therapeutics' (CAPR) recent earnings performance?", "answer": "Capricor Therapeutics (CAPR) recently reported an earnings miss for the quarter ending August 13, 2026, with EPS of -0.70 against an estimate of -0.58. This followed a pattern of inconsistent earnings reports, with a beat in Q2 2026 and a miss in Q1 2026." }, { "question": "What is the technical outlook for Capricor Therapeutics (CAPR)?", "answer": "Technically, Capricor Therapeutics (CAPR) is in a bearish trend, trading below its 50-day and 200-day moving averages ($11.62 and $23.42). While the RSI shows bullish momentum, the MACD indicates weakening momentum, and volume is below average." }, { "question": "What is Capricor Therapeutics' (CAPR) revenue growth outlook?", "answer": "However, Wall Street estimates project next year's revenue to be approximately $56.5 million, with a significant year-over-year growth of +244.00%, though this average is skewed by outlier estimates." }, { "question": "How does Capricor Therapeutics (CAPR) compare to its sector averages?", "answer": "Capricor Therapeutics (CAPR) operates in the Healthcare sector. While sector averages show a median P/E of -3.39 and revenue growth of 8.1%, CAPR's P/E is not applicable due to negative EPS, and its revenue growth is not provided, indicating it is not currently comparable on these metrics." }, { "question": "What is Capricor Therapeutics' (CAPR) stock price prediction for 2030?", "answer": "Based on Monte Carlo simulations, Capricor Therapeutics' (CAPR) projected base case price for 2030 is $6.67, with a downside projection of $1.85 and an upside projection of $24.02. These are statistical simulation outcomes, not guaranteed price targets." } ], "related": { "peopleAlsoWatch": [ { "ticker": "ISRG", "name": "Intuitive Surgical Inc. NASDAQ", "price": "$358.08", "change": "+1.37%", "url": "https://clearank.com/stock/intuitive-surgical-isrg/" }, { "ticker": "LEGN", "name": "Legend Biotech Corporation NASDAQ", "price": "$19.91", "change": "-2.83%", "url": "https://clearank.com/stock/legend-biotech-legn/" }, { "ticker": "MRNA", "name": "Moderna Inc. NASDAQ", "price": "$148.15", "change": "+8.44%", "url": "https://clearank.com/stock/moderna-mrna/" }, { "ticker": "PFE", "name": "Pfizer Inc. NYSE", "price": "$27.78", "change": "-0.0360%", "url": "https://clearank.com/stock/pfizer-pfe/" }, { "ticker": "HCA", "name": "HCA Healthcare, Inc. NYSE", "price": "$417.37", "change": "-1.06%", "url": "https://clearank.com/stock/hca-healthcare-hca/" }, { "ticker": "MOH", "name": "Molina Healthcare Inc. NYSE", "price": "$200.28", "change": "+3.17%", "url": "https://clearank.com/stock/moh-stock-analysis/" }, { "ticker": "ABT", "name": "Abbott Laboratories NYSE", "price": "$103.36", "change": "-1.78%", "url": "https://clearank.com/stock/abbott-laboratories-abt/" }, { "ticker": "FBRX", "name": "Forte Biosciences, Inc. NASDAQ", "price": "$76.99", "change": "+0.00%", "url": "https://clearank.com/stock/fbrx-stock-analysis/" } ], "comparisons": [ { "ticker": "COST vs WMT Comparison", "name": "", "url": "https://clearank.com/compare/cost-vs-wmt/" }, { "ticker": "Gold vs Bitcoin Analysis and Targets", "name": "", "url": "https://clearank.com/compare/gold-vs-bitcoin/" }, { "ticker": "AMAT vs LRCX Comparison", "name": "", "url": "https://clearank.com/compare/amat-vs-lrcx/" } ], "sectorHub": { "text": "Browse all Healthcare →", "url": "https://clearank.com/sector/healthcare/" }, "Newly Tracked": [ { "ticker": "ILMN", "text": "Illumina Inc.", "url": "https://clearank.com/stock/ilmn-stock-analysis/" }, { "ticker": "PCAR", "text": "PACCAR Inc.", "url": "https://clearank.com/stock/pcar-stock-analysis/" }, { "ticker": "O", "text": "Realty Income Corp.", "url": "https://clearank.com/stock/o-stock-analysis/" }, { "ticker": "SPG", "text": "Simon Property Group Inc.", "url": "https://clearank.com/stock/spg-stock-analysis/" }, { "ticker": "JCI", "text": "Johnson Controls International", "url": "https://clearank.com/stock/jci-stock-analysis/" } ], "Top Movers (24h)": [ { "ticker": "REPL", "text": "↓ 8.37%", "url": "https://clearank.com/stock/repl-stock-analysis/" }, { "ticker": "ALGO/USD", "text": "↓ 8.21%", "url": "https://clearank.com/crypto/algorand-algo-usd/" }, { "ticker": "SOXL", "text": "↓ 8.03%", "url": "https://clearank.com/etf/direxion-semiconductor-bull-soxl/" }, { "ticker": "WOLF", "text": "↓ 7.73%", "url": "https://clearank.com/stock/wolfspeed-wolf/" }, { "ticker": "NEAR/USD", "text": "↑ 18.46%", "url": "https://clearank.com/crypto/near-protocol-near-usd/" } ], "Also in Healthcare": [ { "ticker": "BNTX", "text": "BioNTech SE", "url": "https://clearank.com/stock/bntx-stock-analysis/" }, { "ticker": "CRNX", "text": "Crinetics Pharmaceuticals", "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/" }, { "ticker": "CRSP", "text": "CRISPR Therapeutics AG", "url": "https://clearank.com/stock/crispr-therapeutics-crsp/" }, { "ticker": "FBRX", "text": "Forte", "url": "https://clearank.com/stock/fbrx-stock-analysis/" }, { "ticker": "IONS", "text": "Ionis", "url": "https://clearank.com/stock/ions-stock-analysis/" } ] }, "schema": [ { "@context": "https://schema.org", "@graph": [ { "@type": "Place", "@id": "https://clearank.com/#place", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" } }, { "@type": "Organization", "@id": "https://clearank.com/#organization", "name": "CleaRank", "url": "https://clearank.com", "sameAs": [ "https://twitter.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank" ], "email": "info@clearank.com", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" }, "logo": { "@type": "ImageObject", "@id": "https://clearank.com/#logo", "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "caption": "CleaRank", "inLanguage": "en-US", "width": "336", "height": "153" }, "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise", "numberOfEmployees": { "@type": "QuantitativeValue", "value": "40" }, "location": { "@id": "https://clearank.com/#place" } }, { "@type": "WebSite", "@id": "https://clearank.com/#website", "url": "https://clearank.com", "name": "CleaRank", "publisher": { "@id": "https://clearank.com/#organization" }, "inLanguage": "en-US" }, { "@type": "ImageObject", "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png", "url": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png", "width": "1200", "height": "630", "caption": "CleaRank head-to-head comparison", "inLanguage": "en-US" }, { "@type": "BreadcrumbList", "@id": "https://clearank.com/stock/capr-stock-analysis/#breadcrumb", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://clearank.com", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://clearank.com/stock/capr-stock-analysis/", "name": "Capricor Therapeutics, Inc. (CAPR) Stock Analysis" } } ] }, { "@type": "WebPage", "@id": "https://clearank.com/stock/capr-stock-analysis/#webpage", "url": "https://clearank.com/stock/capr-stock-analysis/", "name": "Capricor Therapeutics, Inc (CAPR) Stock Forecast (2026)", "datePublished": "2026-09-03T06:30:28+00:00", "dateModified": "2026-09-11T13:17:25+00:00", "isPartOf": { "@id": "https://clearank.com/#website" }, "primaryImageOfPage": { "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png" }, "inLanguage": "en-US", "breadcrumb": { "@id": "https://clearank.com/stock/capr-stock-analysis/#breadcrumb" } }, { "@type": "Organization", "@id": "https://clearank.com/writer/clearank/", "name": "CleaRank", "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.", "url": "https://clearank.com/writer/clearank/", "image": { "@type": "ImageObject", "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g", "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g", "caption": "CleaRank", "inLanguage": "en-US" }, "sameAs": [ "https://clearank.com/", "https://twitter.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank" ], "worksFor": { "@id": "https://clearank.com/#organization" }, "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg" }, { "@type": "Article", "headline": "Capricor Therapeutics, Inc (CAPR) Stock Forecast (2026)", "datePublished": "2026-09-03T06:30:28+00:00", "dateModified": "2026-09-11T13:17:25+00:00", "author": { "@id": "https://clearank.com/writer/clearank/", "name": "CleaRank" }, "publisher": { "@id": "https://clearank.com/#organization" }, "description": "Capricor Therapeutics, Inc. (CAPR) stock: Healthcare, Biotechnology. $483M market cap. AI rating, technicals, 2030 forecast and trade plans.", "name": "Capricor Therapeutics, Inc (CAPR) Stock Forecast (2026)", "@id": "https://clearank.com/stock/capr-stock-analysis/#richSnippet", "isPartOf": { "@id": "https://clearank.com/stock/capr-stock-analysis/#webpage" }, "image": { "@id": "https://clearank.com/wp-content/uploads/2026/06/comparison-og-default.png" }, "inLanguage": "en-US", "mainEntityOfPage": { "@id": "https://clearank.com/stock/capr-stock-analysis/#webpage" } } ] }, { "@context": "https://schema.org", "@type": "FinancialProduct", "name": "Capricor Therapeutics, Inc. (CAPR)", "tickerSymbol": "CAPR", "url": "https://clearank.com/stock/capr-stock-analysis/", "description": "AI-powered financial analysis for Capricor Therapeutics, Inc. (CAPR) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.", "exchange": "NASDAQ", "offers": { "@type": "Offer", "price": 8.3, "priceCurrency": "USD", "availability": "https://schema.org/InStock", "url": "https://clearank.com/stock/capr-stock-analysis/", "priceValidUntil": "2026-09-12" } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is Capricor Therapeutics (CAPR) stock a buy?", "acceptedAnswer": { "@type": "Answer", "text": "Capricor Therapeutics (CAPR) is currently rated a 'Hold' by Wall Street analysts, with a consensus score of 61 out of 100. While the median price target of $26.50 suggests significant upside potential from the current $8.30, substantial insider selling and a recent earnings miss present considerable risks." } }, { "@type": "Question", "name": "What is Capricor Therapeutics' (CAPR) price target?", "acceptedAnswer": { "@type": "Answer", "text": "The median analyst price target for Capricor Therapeutics (CAPR) is $26.50, with a high of $54.00 and a low of $7.00. This median target represents a potential upside of 219.3% from the current stock price of $8.30." } }, { "@type": "Question", "name": "What are the biggest risks for Capricor Therapeutics (CAPR)?", "acceptedAnswer": { "@type": "Answer", "text": "The primary risks for Capricor Therapeutics (CAPR) include significant insider selling totaling $8.4 million, a negative EPS of -2.45, and trading below key moving averages. The company also recently reported a substantial earnings miss, raising concerns about its operational performance." } }, { "@type": "Question", "name": "How is Capricor Therapeutics' (CAPR) recent earnings performance?", "acceptedAnswer": { "@type": "Answer", "text": "Capricor Therapeutics (CAPR) recently reported an earnings miss for the quarter ending August 13, 2026, with EPS of -0.70 against an estimate of -0.58. This followed a pattern of inconsistent earnings reports, with a beat in Q2 2026 and a miss in Q1 2026." } }, { "@type": "Question", "name": "What is the technical outlook for Capricor Therapeutics (CAPR)?", "acceptedAnswer": { "@type": "Answer", "text": "Technically, Capricor Therapeutics (CAPR) is in a bearish trend, trading below its 50-day ($11.62) and 200-day ($23.42) moving averages. While the RSI shows bullish momentum, the MACD indicates weakening momentum, and volume is below average." } }, { "@type": "Question", "name": "What is Capricor Therapeutics' (CAPR) revenue growth outlook?", "acceptedAnswer": { "@type": "Answer", "text": "However, Wall Street estimates project next year's revenue to be approximately $56.5 million, with a significant year-over-year growth of +244.00%, though this average is skewed by outlier estimates." } }, { "@type": "Question", "name": "How does Capricor Therapeutics (CAPR) compare to its sector averages?", "acceptedAnswer": { "@type": "Answer", "text": "Capricor Therapeutics (CAPR) operates in the Healthcare sector. While sector averages show a median P/E of -3.39 and revenue growth of 8.1%, CAPR's P/E is not applicable due to negative EPS, and its revenue growth is not provided, indicating it is not currently comparable on these metrics." } }, { "@type": "Question", "name": "What is Capricor Therapeutics' (CAPR) stock price prediction for 2030?", "acceptedAnswer": { "@type": "Answer", "text": "Based on Monte Carlo simulations, Capricor Therapeutics' (CAPR) projected base case price for 2030 is $6.67, with a downside projection of $1.85 and an upside projection of $24.02. These are statistical simulation outcomes, not guaranteed price targets." } } ] } ] }